Taiwan develops microfluidic platform for rapid screening of diseases

  18 January 2021

Taiwan’s Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the health and well-being of patients.

Global research shows that 50% usage of antibiotics is inappropriate, and empirical treatment is one of the main causes. Empirical treatment usually gives 2~3 antibiotics at the same time to suppress unknown bacteria. However, no medical device currently in the market is able to conduct an antibiotics combination test to either confirm or predict if a combination is effective. Moreover, the current, time-consuming procedure for antimicrobial susceptibility test (AST) needs to be addressed urgently.

fAST: Platform for Rapid Detection and Screening of Disease Diagnoses

MedFluid’s Personalized Antibiotic Screening Platform fAST automates both genotype and phenotype detections to identify bacteria within 1.5 hours and finish the multiple antibiotics combination test within 5 hours.

Further reading: BioSpectrum Asia
Author(s): BioSpectrum Asia
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!